Treatment and Management of Neuromuscular Channelopathies

Lydia Sharp, Jaya R. Trivedi

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations


Neuromuscular channelopathies are heterogeneous disorders with marked phenotypic and genotypic variability. These include non-dystrophic myotonia (NDM), periodic paralysis (PP), and congenital myasthenic syndrome (CMS). Their diverse clinical manifestations remain a challenge in diagnosis and management to this date. These disorders impact quality of life and cause lifelong disabling symptoms. Treatment options are few and not FDA-approved. This is largely due to a paucity of large, randomized clinical trials in these rare diseases. Challenges of conducting such trials include the rarity of these disorders and the genetic heterogeneity. Physicians rely on off-label use of drugs to treat muscle channelopathies to reduce morbidity and improve quality of life. Besides pharmacological treatment, dietary modifications, lifestyle changes, awareness of triggers, and genetic counseling also play an important role in long-term disease management. This article reviews the current management strategies for neuromuscular channelopathies.

Original languageEnglish (US)
Article number313
JournalCurrent Treatment Options in Neurology
Issue number10
StatePublished - Oct 1 2014


  • Acetazolamide
  • Andersen-Tawil syndrome
  • Channelopathies
  • Congenital myasthenic syndrome
  • Fluoxetine
  • Heterogeneous
  • Hyperkalemia
  • Hypokalemia
  • Mexiletine
  • Non-dystrophic myotonia
  • Periodic paralysis
  • Potassium
  • Quinidine

ASJC Scopus subject areas

  • Clinical Neurology


Dive into the research topics of 'Treatment and Management of Neuromuscular Channelopathies'. Together they form a unique fingerprint.

Cite this